ArticleThe oncologist2017
Article in The oncologist, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Gastric cancer detection by non-blood-based liquid biopsies: A systematic review looking into the last decade of research.United European gastroenterology journal · 2023Pooled it
- A scoping review of DNA methylation biomarkers for non-invasive detection of colorectal cancer at the CpG site level.Clinical epigenetics · 2026Article
- ARMS-qPCR-Based Detection of BRAF and TERT Promoter Mutations: A Cost-Effective Strategy for Molecular Diagnosis of Papillary Thyroid Carcinoma.International journal of endocrinology · 2026Article
- Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics.Experimental hematology & oncology · 2025Review
- DNA methylation drives a new path in gastric cancer early detection: Current impact and prospects.Genes & diseases · 2024Review
- The expression level of chicken telomerase reverse transcriptase in tumors induced by ALV-J is positively correlated with methylation and mutation of its promoter region.Veterinary research · 2022Article
- DNA Methylation: An Important Biomarker and Therapeutic Target for Gastric Cancer.Frontiers in genetics · 2022Review
- Telomerase Regulation: A Role for Epigenetics.Cancers · 2021Review
- Telomeres and telomerase in oncogenesis.Oncology letters · 2020Review
- Telomere-related Markers for Cancer.Current topics in medicinal chemistry · 2020Review
- Role of DNA Methylation in the Resistance to Therapy in Solid Tumors.Frontiers in oncology · 2020Review
- Telomerase Reverse Transcriptase (TERT) Regulation in Thyroid Cancer: A Review.Frontiers in endocrinology · 2020Review
- Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players.Oncogene · 2019Review
- Telomerase Reverse Transcriptase (TERT) in Action: Cross-Talking with Epigenetics.International journal of molecular sciences · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is a high demand for noninvasive screening tools for gastrointestinal cancer (GIC) detection, and GIC-specific markers are required for such purposes. It is established that induction of the telomerase reverse transcriptase gene ( MATERIALS AND
methodsSixty-nine GIC patients (34 colorectal carcinoma and 35 gastric cancer) and 62 healthy adults were recruited and fecal samples were collected. Paired tumors and adjacent non-cancerous tissues from 34 patients and normal mucosa tissues from 12 healthy individuals were collected.
resultsWe identified two GIC-specific methylation sites at -218 (CpG site 1) and -210 (CpG site 2) in the
conclusionThis proof-of-concept study suggests the feasibility of stool IMPLICATIONS FOR PRACTICE: Induction of telomerase reverse transcriptase (TERT) expression coupled with telomerase activation is essential for cancer development/progression, while aberrant TERT promoter methylation has been linked to TERT induction in oncogenesis. We identified two cancer-specific methylation sites (CpG1 and 2) in the TERT promoter in tumors from GIC patients. Methylated TERT promoter CpG sites 1 and 2 were detectable in patient stool, while only background levels were observed in healthy individuals. The sensitivity and specificity was comparable to other known stool methylation markers for GIC detection. This proof-of-concept study suggests the feasibility of stool TERT promoter methylation analyses for noninvasive screening of GIC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.